Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR066712)
National Center for Advancing Translational Sciences (UL1 TR001082-04)
National Institute of Allergy and Infectious Diseases (U01 AI101981)
Walter S. and Lucienne Driskill Foundation
Received: 26 January 2021
Accepted: 10 May 2021
First Online: 6 June 2021
: All study procedures had ethics approval by the Colorado Multiple Institutional Review Board (#13-2606). Written informed consent was obtained from all subjects.
: Not applicable
: ED is an author on licensed patent no. 8,975,033, entitled “Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases.” MKD, JMN, VMK, KDD, and ED have received research support from Pfizer Inc. on studies related to RA. ED has received research support from Bristol Myers Squibb and Celgene, and VMH and KDD have research support from Janssen on studies related to RA. All other authors declare that they have no competing interests.